COVID-19 and Solid Organ Transplantation: Role of Anti-SARS-CoV-2 Monoclonal Antibodies.
Abhay DhandRaymund R RazonablePublished in: Current transplantation reports (2022)
Anti-SARS-CoV-2 antibodies are currently authorized for treatment of mild-moderate COVID-19 and post-exposure prophylaxis, including in SOTRs. Potential future uses include pre-exposure prophylaxis in certain high-risk persons and synergistic use along with emerging oral treatment options. Successful timely administration of anti-SARS-CoV-2 monoclonal antibodies requires a multidisciplinary team approach, effective communication between patients and providers, awareness of circulating viral variants, acknowledgement of various biases affecting treatment, and close monitoring for efficacy and tolerability.
Keyphrases
- sars cov
- respiratory syndrome coronavirus
- end stage renal disease
- coronavirus disease
- newly diagnosed
- ejection fraction
- chronic kidney disease
- clinical trial
- prognostic factors
- randomized controlled trial
- gene expression
- combination therapy
- bone marrow
- open label
- current status
- climate change
- copy number
- smoking cessation
- replacement therapy
- human health